Farzan Nima
Insider CIK 1808296 · KROS Director · KNTE Chief Executive Officer, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics, Inc. | S Sale | 2026-06-04 | 2026-06-08 | 2,625 | $10.73 | $28.2K | 9,767 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2026-06-03 | 2026-06-05 | 7,433 | — | $0 | 7,433 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award | 2026-06-03 | 2026-06-05 | 7,142 | — | $0 | 12,392 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2025-06-04 | 2025-06-06 | 10,500 | — | $0 | 10,500 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award | 2025-06-04 | 2025-06-06 | 5,250 | — | $0 | 5,250 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2024-05-30 | 2024-06-03 | 10,000 | — | $0 | 10,000 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer deriv | 2024-04-03 | 2024-04-05 | 400,000 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer deriv | 2024-04-03 | 2024-04-05 | 275,000 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer deriv | 2024-04-03 | 2024-04-05 | 750,000 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer deriv | 2024-04-03 | 2024-04-05 | 1,281,642 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer deriv | 2024-04-03 | 2024-04-05 | 437,413 | — | $0 | 0 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | D To issuer | 2024-04-03 | 2024-04-05 | 2,186 | — | $0 | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2023-06-06 | 2023-06-08 | 10,000 | — | $0 | 10,000 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | A Award deriv | 2023-02-10 | 2023-02-14 | 750,000 | — | $0 | 215,000 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | A Award deriv | 2023-02-10 | 2023-02-15 | 750,000 | — | $0 | 750,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2022-06-01 | 2022-06-03 | 8,293 | — | $0 | 8,293 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | A Award deriv | 2022-02-11 | 2022-02-15 | 400,000 | — | $0 | 400,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2021-06-01 | 2021-06-03 | 8,293 | — | $0 | 8,293 | SEC↗ |
| KNTE Kinnate Biopharma Inc. | A Award deriv | 2021-02-12 | 2021-02-16 | 275,000 | — | $0 | 275,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2020-05-29 | 2020-05-29 | 8,500 | — | $0 | 8,500 | SEC↗ |